Integrated 15-GEP and PRAME Classifier Shows Prognostic Accuracy in Uveal Melanoma
Source: Onclive, August 2024
Integrating 15-GEP with PRAME expression status into a 4-group prognostic classification system showed prognostic accuracy in uveal melanoma.
An integrated 15-gene expression profile (15-GEP) and PRAME RNA expression classifier demonstrated prognostic accuracy in patients with uveal melanoma, according to data from the Collaborative Ocular Oncology Group Study Number 2 (COOG2) published in the Journal of Clinical Oncology.
In the largest prospective multicenter prognostic biomarker study performed to date, the 5-year metastasis-free survival (MFS) rate among patients with PRAME-negative tumors (n = 1106) was 86.6% (95% CI, 84.2%-89.1%) compared with 63.7% (95% CI, 58.5%-69.3%) among patients with PRAME-positive tumors (n = 471). At the median follow-up of 43.6 months, the 5-year melanoma-specific survival (MSS) rates were 93.1% (95% CI, 91.2%-95.0%) vs 78.5% (95% CI, 73.9%-83.3%), respectively.